These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17685740)

  • 21. Empirically supported treatments for panic disorder.
    McHugh RK; Smits JA; Otto MW
    Psychiatr Clin North Am; 2009 Sep; 32(3):593-610. PubMed ID: 19716992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study.
    Bertani A; Perna G; Arancio C; Caldirola D; Bellodi L
    J Clin Psychopharmacol; 1997 Apr; 17(2):97-101. PubMed ID: 10950471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder.
    Roy-Byrne PP; Craske MG; Stein MB; Sullivan G; Bystritsky A; Katon W; Golinelli D; Sherbourne CD
    Arch Gen Psychiatry; 2005 Mar; 62(3):290-8. PubMed ID: 15753242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.
    Mavissakalian MR; Schmier JK; Flynn JA; Revicki DA
    Pharmacoeconomics; 2000 Oct; 18(4):383-91. PubMed ID: 15344306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Locus of control orientation in panic disorder and the differential effects of treatment.
    Bakker A; Spinhoven P; van der Does AJ; van Balkom AJ; van Dyck R
    Psychother Psychosom; 2002; 71(2):85-9. PubMed ID: 11844944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder.
    Hicks TV; Leitenberg H; Barlow DH; Gorman JM; Shear MK; Woods SW
    J Consult Clin Psychol; 2005 Jun; 73(3):506-14. PubMed ID: 15982148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of treatment resistance on depressive relapse following electroconvulsive therapy.
    Flint A
    Acta Psychiatr Scand; 1997 Nov; 96(5):405-6. PubMed ID: 9395161
    [No Abstract]   [Full Text] [Related]  

  • 28. [Analysis of the cost and the effectiveness of a psychotherapy for panic disorder with agoraphobia (PDA) versus a treatment combining pharmacotherapy and psychotherapy].
    Marchand A; Germain V; Reinharz D; Mainguy N; Landry P
    Sante Ment Que; 2004; 29(2):201-20. PubMed ID: 15928793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incremental cost-effectiveness of a collaborative care intervention for panic disorder.
    Katon W; Russo J; Sherbourne C; Stein MB; Craske M; Fan MY; Roy-Byrne P
    Psychol Med; 2006 Mar; 36(3):353-63. PubMed ID: 16403243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
    Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E
    BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
    Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH
    JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies.
    Otto MW; Deveney C
    J Clin Psychiatry; 2005; 66 Suppl 4():28-32. PubMed ID: 15842185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discussion of "methodological controversies in the treatment of panic disorder".
    Klein DF
    Behav Res Ther; 1996; 34(11-12):849-53; discussion 855-63. PubMed ID: 8990537
    [No Abstract]   [Full Text] [Related]  

  • 35. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
    Pecknold JC; Luthe L; Iny L; Ramdoyal D
    J Psychiatry Neurosci; 1995 May; 20(3):193-8. PubMed ID: 7786880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive-behavioral therapy for panic disorder: a review of treatment elements, strategies, and outcomes.
    Rayburn NR; Otto MW
    CNS Spectr; 2003 May; 8(5):356-62. PubMed ID: 12766691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder.
    Clark DM; Salkovskis PM; Hackmann A; Middleton H; Anastasiades P; Gelder M
    Br J Psychiatry; 1994 Jun; 164(6):759-69. PubMed ID: 7952982
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.